Express News | Savara Inc. : Oppenheimer Raises Target Price to $11 From $9.5

ReutersMay 21 08:10 ET

Savara Is Maintained at Outperform by Oppenheimer

Savara Is Maintained at Outperform by Oppenheimer

Dow JonesMay 21 08:10 ET

Express News | Oppenheimer Maintains Outperform on Savara, Raises Price Target to $11

BenzingaMay 21 07:59 ET

Analysts Are Bullish on These Healthcare Stocks: Savara (SVRA), Allogene Therapeutics (ALLO)

TipRanksMay 21 07:50 ET

Reported Sunday, Savara And Trillium Health Presented New Data On Autoimmune Pulmonary Alveolar Proteinosis At ATS 2024

Below are summaries of the posters presented:Poster Board 701: "Healthcare Burden of Pulmonary Alveolar Proteinosis" presented by E. Lee, M.D., Ph.D.; sponsored by Savara Inc.Presented data from a ret

BenzingaMay 20 01:46 ET

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the American Thoracic Society (ATS) International Conference 2024

Savara's Partner, Trillium Health LLC, Presented Data on the Laboratory Blood Test for Diagnosing aPAP Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory

BusinesswireMay 19 12:15 ET